Fig. 3.

miR-138-5p and miR-138–2-3p reduce cellular proliferation and migration abilities of ccRCC cells. a Transwell assay. 786-O cells were transfected with miR-138-5p mimics, miR-138-5p inhibitor or with the appropriate negative controls. After transfection, their migration ability was examined by transwell assay (left). Number of the migrated cells were scored (right). Similarly, 786-O cells were transfected with miR-138–2-3p mimics, miR-138–2-3p inhibitor or with the appropriate negative controls. After transfection, their migration ability was examined by transwell assay (left). Number of the migrated cells were scored (right). b Transwell assay. CAK-1 cells were transfected as in a. After transfection, their migration ability was examined by transwell assay (left). Number of the migrated cells were scored (right) (n = 3). c CCK-8 assay. 786-O cells were transfected as in (a). At the indicated time points after transfection, cell viability was examined by CCK-8 assay (n = 3). (d) EdU assay. 786-O cells were transfected as in (a). After transfection, cells were subjected to EdU assay. Cell nuclei were stained with Hoechst